ArticleJournal of fluorescence2025
Fluorescent Microorganism-Based Composite: Enhancing Curcumin Delivery Efficiency and its Antitumor Application in Prostate Cancer.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is a major global health concern, ranking as the second most common malignancy in men and the fifth leading cause of cancer-related deaths. Although curcumin exhibits potent antioxidant, anti-inflammatory, and antitumor properties, its clinical application is limited by poor solubility, low bioavailability, and rapid metabolism. In this study, we developed a microorganism-metal-organic framework (MOF)-based carrier (1-CP1) by combining a novel Zn(II) coordination polymer, [Zn(Hbcb)(PYTPY)] (1), with CP1. The carrier, loaded with curcumin to form 1-CP1@Curcumin, significantly enhanced the solubility, bioavailability, and stability of curcumin. Fluorescence assays revealed that the composite demonstrated a fluorescence emission peak at 511 nm, with a strong response to Fe³⁺ ions, showing a quenching efficiency of over 95%. In vitro experiments on LNCaP prostate cancer cells showed that 1-CP1@Curcumin significantly inhibited cell viability, with a reduction of approximately 50% at 20 µM curcumin concentration after 48 h of treatment. Additionally, quantitative PCR analysis of apoptosis-related gene expression revealed a significant decrease in Bcl-2 mRNA levels, indicating that the composite induced apoptosis in prostate cancer cells. These results highlight that 1-CP1@Curcumin effectively overcomes curcumin's delivery limitations and offers strong antitumor efficacy, providing an innovative platform for potential clinical applications in prostate cancer therapy.
Indexed as
Identifiers
39954179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.